https://www.selleckchem.com/pr....oducts/lonafarnib-sc
ypes. As MDT care becomes more widely adopted in the treatment of melanoma, accurate diagnosis and staging are important, as clinical outcomes for stage III disease vary widely by substage. Because ~50% of melanomas harbor BRAF mutations, testing is important for an informed treatment decision. Interdisciplinary physician-patient engagement throughout the course of treatment can improve comorbidity and adverse event management to optimize patients' treatment journeys. At diagnosis, the majority of patients with intrahepatic
Like
Comment
Share
